Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

Juan Carlos Montero(Centro de Investigación del Cáncer), Atanasio Pandiella(Complejo Hospitalario Universitario de Albacete)

Journal of Experimental & Clinical Cancer Research

March 22, 2022

10.1186/s13046-022-02330-4

Cited by 23

Related Papers

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

|Blood|2008|89

Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells

|JNCI Journal of the National Cancer Institute|2010|48

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2

|Oncotarget|2015|19

An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

|Journal of Experimental & Clinical Cancer Research|2023|10

Regulation of the prometastatic neuregulin–<scp>MMP</scp>13 axis by <scp>SRC</scp> family kinases: therapeutic implications

|Molecular Oncology|2017|9